直立性低血压药物市场－全球产业规模、份额、趋势、机会和预测（按产品、诊断测试类型、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球直立性低血压药物市场价值为 5.4226 亿美元，预计到 2030 年将以 8.26% 的复合年增长率成长。直立性低血压或姿势性低血压是指站立时血压突然下降，导致头晕、昏厥和疲劳等症状。虽然这种情况通常是暂时的，但也可能表明更严重的潜在健康问题，尤其是对于老年人或高血压患者。市场受益于人们意识的不断增强（尤其是老龄化人口）和诊断能力的提高。临床工具和诊断协议的创新（例如动态血压监测）有助于及时发现和治疗。此外，人们越来越关注老年人和高血压患者中直立性低血压的盛行率，特别是在发展中地区，这刺激了对旨在改善患者预后和降低心血管风险的有效药物疗法的需求。

关键市场驱动因素

医学诊断的进步

主要市场挑战

合併症和复杂的患者情况

主要市场趋势

神经源性直立性低血压（nOH）焦点

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球直立性低血压药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产物（屈昔多巴、氟氢可的松、吲哚美辛、盐酸米多君、非类固醇抗发炎药、吡斯的明）
  • 依诊断测试类型（血液检查、心电图、超音波心动图、压力测试）
  • 按最终使用者（门诊手术中心、诊断中心、医院和诊所）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区直立性低血压药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲直立性低血压药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第八章：北美直立性低血压药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第九章：南美洲直立性低血压药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲直立性低血压药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球直立性低血压药物市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Mylan NV
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Orthostatic Hypotension Drugs Market was valued at USD 542.26 million in 2024 and is projected to grow at a CAGR of 8.26% through 2030. Orthostatic hypotension, or postural hypotension, involves a sudden drop in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and fatigue. While often transient, the condition can also indicate more serious underlying health issues, especially in older or hypertensive individuals. The market benefits from growing awareness, especially among aging populations, and improved diagnostic capabilities. Innovations in clinical tools and diagnostic protocols-such as dynamic blood pressure monitoring-are facilitating timely detection and treatment. Additionally, rising attention to orthostatic hypotension's prevalence among elderly and hypertensive patients, particularly in developing regions, is spurring demand for effective pharmaceutical therapies aimed at improving patient outcomes and reducing cardiovascular risk.

Key Market Drivers

Advancements in Medical Diagnostics

Medical diagnostics have seen transformative progress, significantly influencing the management of orthostatic hypotension. Advanced molecular tools such as PCR, next-generation sequencing, and gene profiling now enable precise disease detection and characterization. Liquid biopsies offer a non-invasive method for monitoring disease biomarkers, aiding early diagnosis and treatment response. Additionally, point-of-care devices have become more efficient, providing rapid results critical for conditions like blood pressure abnormalities. Imaging advancements-including MRI, CT, and PET-further improve disease visualization and understanding. Artificial intelligence is increasingly applied to analyze complex datasets, supporting diagnostic accuracy and treatment planning. Omics-based biomarker discovery is fostering new diagnostic tests for cardiovascular and neurodegenerative diseases. Notably, a 2024 statement by the American Heart Association emphasized improved diagnosis and management strategies for orthostatic hypotension in hypertensive patients, highlighting the growing clinical focus on this condition and the need for targeted therapies to enhance patient outcomes

Key Market Challenges

Comorbidities and Complex Patient Profiles

Managing orthostatic hypotension becomes increasingly difficult in patients with multiple coexisting conditions such as diabetes, hypertension, or cardiovascular disease. Many of these individuals are on complex medication regimens, increasing the risk of adverse drug interactions and complicating treatment decisions. Polypharmacy often undermines the effectiveness of orthostatic hypotension drugs and raises safety concerns. Customized treatment approaches are necessary to address each patient's unique health profile, which may demand frequent monitoring and ongoing adjustments to therapy. Additionally, patients with overlapping conditions like neurodegenerative disorders face an elevated risk of falls, requiring holistic care strategies. Understanding the complex interplay between various diseases and their impact on blood pressure regulation is vital to delivering effective and safe treatment solutions.

Key Market Trends

Neurogenic Orthostatic Hypotension (nOH) Focus

There is growing clinical and commercial interest in neurogenic orthostatic hypotension (nOH) as a distinct subset of the broader condition. Common in patients with neurological disorders, nOH is increasingly recognized due to improved diagnostic awareness and specialized testing. This subtype, typically involving impaired norepinephrine release, has prompted the development of targeted therapies aimed at improving blood pressure stability. Ongoing clinical trials are evaluating nOH-specific treatments, contributing to a robust pipeline of potential new therapies. Patient advocacy groups and neurological foundations are helping raise awareness and accelerate research in this space. Personalized care strategies are being adopted to address the unique clinical needs of nOH patients. Furthermore, diagnostic advances-such as autonomic function testing-are enhancing accuracy and supporting precision treatment. Pharmaceutical companies are investing in innovative drug classes, including norepinephrine prodrugs and reuptake inhibitors, to meet the specific demands of this growing patient population.

Key Market Players

• Mylan N.V.
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

Report Scope:

In this report, the Global Orthostatic Hypotension Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthostatic Hypotension Drugs Market, By Product:

• Droxidopa
• Fludrocortisone
• Indomethacin
• Midodrine Hydrochloride
• NSAIDs
• Pyridostigmine

Orthostatic Hypotension Drugs Market, By Diagnostics Test Type:

• Blood Tests
• ECG
• Echocardiogram
• Stress Test

Orthostatic Hypotension Drugs Market, By End-User:

• Ambulatory Surgical Centers
• Clinics & Hospitals
• Diagnostic Centers

Orthostatic Hypotension Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthostatic Hypotension Drugs Market.

Available Customizations:

Global Orthostatic Hypotension Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthostatic Hypotension Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine)
  • 5.2.2. By Diagnostics Test Type (Blood Tests, ECG, Echocardiogram, Stress Test)
  • 5.2.3. By End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Orthostatic Hypotension Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Diagnostics Test Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Orthostatic Hypotension Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Diagnostics Test Type
      • 6.3.1.2.3. By End User
  • 6.3.2. India Orthostatic Hypotension Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Diagnostics Test Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Orthostatic Hypotension Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Diagnostics Test Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Orthostatic Hypotension Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Diagnostics Test Type
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Orthostatic Hypotension Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Diagnostics Test Type
      • 6.3.5.2.3. By End User

7. Europe Orthostatic Hypotension Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Diagnostics Test Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Orthostatic Hypotension Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Diagnostics Test Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Orthostatic Hypotension Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Diagnostics Test Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Orthostatic Hypotension Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Diagnostics Test Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Orthostatic Hypotension Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Diagnostics Test Type
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Orthostatic Hypotension Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Diagnostics Test Type
      • 7.3.5.2.3. By End User

8. North America Orthostatic Hypotension Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Diagnostics Test Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Orthostatic Hypotension Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Diagnostics Test Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Orthostatic Hypotension Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Diagnostics Test Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Orthostatic Hypotension Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Diagnostics Test Type
      • 8.3.3.2.3. By End User

9. South America Orthostatic Hypotension Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Diagnostics Test Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Orthostatic Hypotension Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Diagnostics Test Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Orthostatic Hypotension Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Diagnostics Test Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Orthostatic Hypotension Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Diagnostics Test Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Orthostatic Hypotension Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Diagnostics Test Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Orthostatic Hypotension Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Diagnostics Test Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Orthostatic Hypotension Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Diagnostics Test Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Orthostatic Hypotension Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Diagnostics Test Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Orthostatic Hypotension Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Mylan N.V.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Upsher-Smith Laboratories, LLC
• 16.3. Chelsea Therapeutics International, Ltd
• 16.4. Amgen Inc
• 16.5. F. Hoffmann-La Roche Ltd
• 16.6. Apotex Inc
• 16.7. Pfizer Inc.
• 16.8. Novartis AG
• 16.9. H. Lundbeck A/S
• 16.10. Amneal Pharmaceuticals LLC

17. Strategic Recommendations

18. About Us & Disclaimer